All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Recovery comparison

BPC-157 vs Cartalax

An educational, source-based comparison of BPC-157 and Cartalax — how each peptide works, what it's researched for, and what to know before going deeper.

Tissue Repair · Gastrointestinal
BPC-157

Body Protection Compound studied for gut and tissue support.

Mechanism

A pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Research suggests it modulates the nitric oxide system, upregulates growth hormone receptors in injured tissue, and promotes angiogenesis (formation of new blood vessels) — mechanisms associated with accelerated tendon, ligament, muscle, and intestinal mucosa repair in preclinical models.

Research areas
  • Tendon-to-bone healing
  • Ligament and muscle recovery
  • Gastric ulcer protection
  • Inflammatory bowel models
  • Neuroprotection (rodent)
Considerations
  • Human clinical trials are limited — most research is preclinical.
  • Not FDA-approved for human therapeutic use.
  • Quality, purity, and dosing of compounded peptides vary widely.
Full BPC-157 profile →
Musculoskeletal · Bioregulator
Cartalax

Tripeptide bioregulator researched for cartilage and joint support.

Mechanism

A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.

Research areas
  • Osteoarthritis and cartilage repair
  • Joint mobility in aging
  • Tendon and ligament integrity
Considerations
  • Preclinical and Russian clinical data only.
  • Not FDA-approved.
Full Cartalax profile →

BPC-157 vs Cartalax — Key differences

  • Class: BPC-157 is classified as Tissue Repair · Gastrointestinal, while Cartalax is Musculoskeletal · Bioregulator.
  • Primary research focus: BPC-157tendon-to-bone healing; Cartalaxosteoarthritis and cartilage repair.
  • Tag: Recovery vs Joint · Bioregulator.

Related comparisons